Generic Name	Tislelizumab Injection	Structure	protein structure
Molecular Formula		Specification Dose	10ml:100mg
Active Ingredients	Humanized IgG4 anti-PD-1 monoclonal antibody	Dosage Form	injection
Agens Type	monocloning antibody	Target	Anti-PD-1 antibody drugs
Mechansim of Action		Clinical Indication	Recurrent or refractory classic Hodgkin's lymphoma, locally advanced or metastatic urothelial carcinoma
Tumor types	Esophageal cancer	Patent Number
OTC		Year of Reference
Adverse Reaction	Fever, hypothyroidism, weight gain, pruritus, decreased white blood cell count, upper respiratory tract infection, elevated alanine aminotransferase (ALT), rash, decreased neutrophil count, cough, fatigue, and elevated blood bilirubin. Adverse reactions of grade 3 and above with an incidence rate of ≥ 2% include pulmonary inflammation, weight gain, severe skin reactions, and hypertension.
References